Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
XOMA Royalty Corporation filings document a biotechnology royalty aggregator with Nasdaq-listed common stock, Series A cumulative perpetual preferred stock, and Series B depositary shares. Form 8-K reports cover operating results, Regulation FD presentations, material definitive agreements, completed acquisition activity, and officer appointments tied to the company’s royalty aggregation strategy.
Proxy materials describe annual meeting procedures, board and stockholder voting matters, and governance disclosures. The filing record also documents the company’s capital structure, including preferred stock classes, and formal disclosures around completed acquisitions and related legacy asset information.
XOMA Royalty Corporation reported a strong turnaround for 2025, with income and revenues rising to $52.1 million from $28.5 million in 2024 and net income improving to $31.7 million from a net loss of $13.8 million.
Cash receipts reached $50.5 million, including $33.6 million in royalties and commercial payments and $16.9 million in milestones and fees, and the company generated positive cash flow from operations. XOMA deployed $25.0 million to acquire additional royalty and milestone assets and repurchased 648,048 common shares for $16.0 million.
At December 31, 2025, XOMA held cash and cash equivalents of $133.7 million, including $50.8 million in restricted cash, against long-term debt of $96.5 million. The portfolio expanded to more than 100 assets, with multiple commercial and late-stage programs supporting growing royalty streams.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp director and Chief Executive Officer Owen Hughes reported new equity awards. On March 16, 2026, he received 126,813 Performance Stock Units, each representing a contingent right to one share of common stock, which vest only if the stock reaches specified price targets and he remains in service.
He was also granted 82,428 restricted stock units payable solely in common stock. These RSUs vest in four equal 25% installments on each of the first four anniversaries of March 11, 2026, subject to continued service. Following these awards, he holds 180,696 common shares directly, 295 common shares indirectly via a 401(k) plan, and 102,000 depositary shares of 8.375% Series B cumulative stock.
Sitko Bradley reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp’s Chief Investment Officer Bradley Sitko reported equity awards rather than market trades. He received 44,849 Performance Stock Units, each representing the right to one share of common stock if specified share-price goals are met and he remains with the company through the vesting dates.
He was also granted two blocks of common-stock RSUs at no cash cost: 30,000 shares and 29,402 shares. One RSU grant vests fully on March 11, 2031, and the other vests 25% on each of the first four anniversaries of March 11, 2026, all conditioned on continued service.
Following these grants, Sitko holds 79,224 shares of common stock directly, plus the 44,849 PSUs. He also reports direct holdings of preferred and depositary shares and additional indirect common and preferred holdings through a 401(k) plan, his spouse, and children.
Trigilio Jeffrey reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp Chief Financial Officer Jeffrey Trigilio received new equity awards that increase his direct ownership stake. On March 11, 2026, he was granted 138,462 Performance Stock Units, each representing a contingent right to one share of common stock, and 90,000 restricted stock units payable in common stock.
The 90,000 restricted stock units vest in four equal 25% installments on the first four anniversaries of January 12, 2026, as long as he continues serving the company. The performance stock units vest only if the common stock reaches a specified price per share and he remains in service through the applicable vesting dates.
Montano Maricel Perea reported acquisition or exercise transactions in this Form 4 filing.
XOMA Royalty Corp reported that Chief Legal Officer Maricel Perea Montano received new equity awards. She was granted 26,289 restricted stock units payable in common stock, which vest in four equal annual installments starting on March 11, 2026, contingent on continued service.
She also received 40,444 performance stock units, each representing a right to one share of common stock. These performance units vest only if the common stock reaches a specified price per share and she remains in service, aligning a portion of her compensation with long-term share performance.
XOMA ROYALTY CORPORATION ownership update: FMR LLC reports beneficial ownership of 1,268,506.14 shares of common stock, representing 10.2% of the class as of 02/27/2026. The filing also notes that Fidelity Contrafund held 773,332 shares, or 6.2%, as of the same date.
The schedule is an amendment (No. 5) and identifies filings and powers of attorney authorizing the submission; Exhibit 99 and related exhibits are referenced for subsidiary and agreement details.
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
XOMA Royalty Corporation has completed its acquisition of Generation Bio Co. through a tender offer followed by a merger. XOMA Royalty’s subsidiary first purchased Generation Bio common shares at $4.2913 per share in cash plus one contingent value right (CVR) per share, then merged the subsidiary into Generation Bio.
As of the tender expiration on February 6, 2026, holders had validly tendered 4,722,533 shares, representing about 70% of Generation Bio’s outstanding stock, satisfying the minimum tender condition. Remaining eligible shares were converted into the same cash-and-CVR package, and Generation Bio is now a wholly owned subsidiary of XOMA Royalty.
XOMA Royalty Corporation and its subsidiary XRA 7 Corp. have completed their tender offer and merger to acquire Generation Bio Co. for $4.2913 in cash plus one contingent value right (CVR) per share. The offer expired on February 6, 2026, with about 4,722,533 shares, or roughly 70% of the company, validly tendered. All tendered shares have been accepted and paid for, and a merger under Delaware law closed on February 9, 2026, making Generation Bio a wholly owned subsidiary of XOMA. Remaining untendered shares (with limited exceptions) were converted into the right to receive the same cash-and-CVR consideration. Generation Bio’s stock has stopped trading on Nasdaq, and the company is moving to delist and deregister its shares and suspend its SEC reporting obligations.
XOMA Royalty Corporation and its subsidiary XRA 7 Corp. have completed their tender offer and merger to acquire Generation Bio Co. for $4.2913 in cash plus one contingent value right (CVR) per share. The offer expired on February 6, 2026, with about 4,722,533 shares, or roughly 70% of the company, validly tendered. All tendered shares have been accepted and paid for, and a merger under Delaware law closed on February 9, 2026, making Generation Bio a wholly owned subsidiary of XOMA. Remaining untendered shares (with limited exceptions) were converted into the right to receive the same cash-and-CVR consideration. Generation Bio’s stock has stopped trading on Nasdaq, and the company is moving to delist and deregister its shares and suspend its SEC reporting obligations.